{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:30:41Z","timestamp":1791513041489,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejmech.2022.114307","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T11:53:23Z","timestamp":1648209203000},"page":"114307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors"],"prefix":"10.1016","volume":"236","author":[{"given":"Hongrui","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youbao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huinan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-1959","authenticated-orcid":false,"given":"Xin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114307_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1083\/jcb.200204026","article-title":"Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production","volume":"158","author":"Umezu-Goto","year":"2002","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114307_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbalip.2012.07.019","article-title":"Lysoglycerophospholipids in chronic inflammatory disorders: the PLA2\/LPC and ATX\/LPA axes","volume":"1831","author":"Sevastou","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2022.114307_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.plipres.2015.02.001","article-title":"Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer","volume":"58","author":"Barbayiannia","year":"2015","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejmech.2022.114307_bib4","first-page":"272","article-title":"Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in\u00a0vivo","volume":"30","author":"Benesch","year":"2016","journal-title":"J.\u00a0Biomed. Res."},{"key":"10.1016\/j.ejmech.2022.114307_bib5","doi-asserted-by":"crossref","first-page":"14312","DOI":"10.1074\/jbc.RA118.004450","article-title":"Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency","volume":"293","author":"Salgado-Polo","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10555-021-09955-5","article-title":"Anti-cancer strategies targeting the autotaxin-lysophosphatidic acid receptor axis: is there a path forward?","volume":"40","author":"Tigyi","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2022.114307_bib7","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1021\/acs.jmedchem.7b00647","article-title":"Discovery, structure-activity relationship and binding mode of imidazo[1,2-a] pyridine series of autotaxin inhibitors","volume":"60","author":"Joncour","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.110.165845","article-title":"A\u00a0novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation","volume":"334","author":"Gierse","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114307_bib9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1124\/mol.115.100404","article-title":"Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding","volume":"88","author":"Stein","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114307_bib10","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of BLD-0409 in healthy subjects (NCT04146805)","year":"2019","journal-title":"ClinicalTrials.gov Web Site"},{"key":"10.1016\/j.ejmech.2022.114307_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1021\/acs.jmedchem.6b01270","article-title":"Highly potent non-cCarboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells","volume":"60","author":"Banerjee","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1021\/acs.jmedchem.6b01743","article-title":"Rational design of autotaxin inhibitors by structural evolution of endogenous modulators","volume":"60","author":"Keune","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib13","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1021\/acs.jmedchem.7b00032","volume":"60","author":"Desroy","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2019-000422","article-title":"Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)","volume":"6","author":"Maher","year":"2019","journal-title":"BMJ Open Resp. Res."},{"key":"10.1016\/j.ejmech.2022.114307_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1158\/1535-7163.MCT-19-0386","article-title":"Inhibition of autotaxin with GLPG1690 increases the efficacy of radiotherapy and chemotherapy in a mouse model of breast cancer","volume":"19","author":"Tang","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114307_bib16","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1021\/acs.jmedchem.0c00506","article-title":"Discovery of novel indole-based allosteric highly potent ATX inhibitors with great in\u00a0vivo efficacy in mouse lung fibrosis model","volume":"63","author":"Lei","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib17","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1021\/jm801335z","article-title":"Synthesis of Casimiro in and optimization of its quinone reductase 2 and aromatase inhibitory activities","volume":"52","author":"Maiti","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/acs.oprd.9b00511","article-title":"Catalyst-free cyclization- and Curtius rearrangement-induced functional group transformation: an improved synthetic strategy of first-in-class ATX inhibitor Ziritaxestat (GLPG-1690)","volume":"24","author":"Lei","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2022.114307_bib19","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.bmcl.2006.08.089","article-title":"A\u00a0novel series of imidazo[1,2-a]pyridine derivatives as HIF-1\u03b1 prolyl hydroxylase inhibitors","volume":"16","author":"Warshakoon","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114307_bib20","doi-asserted-by":"crossref","first-page":"113951","DOI":"10.1016\/j.ejmech.2021.113951","article-title":"Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in\u00a0vivo anti-fibrosis efficacy in rodent model","volume":"227","author":"Lei","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib21","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/ci034043l","article-title":"Development of a method for evaluating drug-likeness and ease of synthesis using a data set in which compounds are assigned scores based on chemists' intuition","volume":"43","author":"Takaoka","year":"2003","journal-title":"J.\u00a0Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.ejmech.2022.114307_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114307_bib23","first-page":"380","article-title":"Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks","volume":"45","author":"Edwards","year":"2010","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114307_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jbior.2018.09.008","article-title":"Regulation of tumor cell \u2013 Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis","volume":"71","author":"Tigyi","year":"2019","journal-title":"Advances in Bio. Reg."},{"key":"10.1016\/j.ejmech.2022.114307_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cancers12010105","article-title":"Autotaxin implication in cancer metastasis and autoimunne disorders: functional implication of binding autotaxin to the cell surface","volume":"12","author":"Peyruchaud","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114307_bib26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11011-018-0233-3","article-title":"Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes","volume":"33","author":"Cholia","year":"2018","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ejmech.2022.114307_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.032","article-title":"CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib","volume":"422","author":"Gou","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejmech.2022.114307_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tiv.2016.09.002","article-title":"Differential mechanistic investigation of protective effects from imperatorin and sec-O-glucosylhamaudol against arsenic trioxide-induced cytotoxicity in\u00a0vitro","volume":"37","author":"Hu","year":"2016","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2022.114307_bib29","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acs.molpharmaceut.5b00821","article-title":"Fluorescence-based transport assays revisited in a human renal proximal tubule cell line","volume":"13","author":"Caetano-Pinto","year":"2016","journal-title":"Mol. Pharm."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422002094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422002094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:43:27Z","timestamp":1759329807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422002094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"alternative-id":["S0223523422002094"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114307","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114307"}}